**Core Concept:**
Urinary obstruction is a common clinical presentation in patients with benign prostatic hyperplasia (BPH). Urinary flow rate is a critical parameter used to assess the severity of obstruction and monitor treatment response. Prostate volume is another important parameter that is typically assessed using ultrasound or other imaging modalities. The goal of pharmacological treatment in BPH is to improve urinary flow rate and relieve symptoms while minimizing changes in prostate size.

**Why the Correct Answer is Right:**
The correct answer is D. Alfuzosin, a selective alpha-1A receptor antagonist, is a first-line drug choice for improving urinary flow rate in patients with BPH. By blocking alpha-1A receptors on smooth muscle cells of the prostatic urethra, alfuzosin relaxes the smooth muscle and reduces prostatic obstruction. This leads to improvement in urinary flow rate and symptom scores without significant changes in prostate volume.

**Why Each Wrong Option is Incorrect:**
A. Terazosin (another alpha-1 receptor antagonist) can also improve urinary flow rate but may cause significant reduction in prostate size, which contradicts the question requirement.
B. Finasteride (a 5-alpha reductase inhibitor) does not directly affect alpha-1 receptors but reduces prostate size, making it unsuitable for improving urinary flow rate without affecting prostate size.
C. Doxazosin (another alpha-1 receptor antagonist) can improve urinary flow rate, but like terazosin, it can also cause significant reduction in prostate size.

**Clinical Pearl:**
Choosing the right drug for treating BPH is crucial to optimize patient outcomes. Selecting an alpha-1 receptor antagonist like alfuzosin ensures improvement in urinary flow rate without compromising prostate size, which is particularly important for maintaining organ integrity and minimizing the risk of complications like urinary retention or acute urinary retention.